Q3 2025

Filed Oct 30, 2025 · 10-Q · 30 days after period end · 0000875045-25-000049

Q3 2025 · 10-Q

Revenue

$2.53B

+2.8% vs Q3 2024

Net Income

$466.50M

+20.1% vs Q3 2024

EPS Diluted

$3.17

+19.2% vs Q3 2024

Operating Cash Flowderived$1,272,500,000+36.0%

Same quarter

Metric	Q3 2025	Q3 2024	Q3 2023	Q3 2022
Revenue	$2.53B	$2.47B	$2.53B	$2.51B
Net Income	$466.50M	$388.50M	-$68.10M	$1.13B
EPS Diluted	$3.17	$2.66	-$0.47	$7.84

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Biogen Inc. · CIK 875045 · Engraved from SEC EDGAR